The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Baseline findings from the SECURE study of incidentally detected MGUS in the UK
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses baseline findings from patients enrolled in the SECURE study (NCT05539079) with incidentally detected monoclonal gammopathy of undetermined significance (MGUS) in the UK. He highlights that most patients were identified in secondary care rather than primary care, with rheumatology, renal and musculoskeletal services among the common settings, and that the cohort was older and had more comorbidities than screened MGUS populations. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Monoclonal gammopathy is currently incidentally identified in UK clinical practice and all the data around progression of MGUS to myeloma has always been done in screening studies and the two excellent screening studies have been the Mayo Clinic study and the iStopMM study in Iceland. So in the UK, we set out to understand, well, people are being picked up incidentally with monoclonal gammopathy...
Monoclonal gammopathy is currently incidentally identified in UK clinical practice and all the data around progression of MGUS to myeloma has always been done in screening studies and the two excellent screening studies have been the Mayo Clinic study and the iStopMM study in Iceland. So in the UK, we set out to understand, well, people are being picked up incidentally with monoclonal gammopathy. Where are they being picked up? You know, what clinical pathways do they follow? You know, and also are there specific characteristics that are in these incidentally MGUS patients which stand out in comparison with, you know, screened MGUS patients is what we wanted to kind of identify. So this study has now recruited about 1,500 patients and in the paper that has been published we looked at the first 900 odd patients and what was striking to us in the UK was we expected the majority of the patients to have been picked up in primary care, meaning in GP surgeries, but that’s not the case. The majority of the patients were first diagnosed with MGUS in a secondary care hospital, often in units such as rheumatology, you know, renal medicine or musculoskeletal departments is where these patients are being picked up. So this was very interesting. And then the other comparison that we made with the screened cohorts of the iStopMM as well as the Mayo Clinic cohorts is these patients have higher comorbidities and also are more advanced in age in comparison to the cohorts which have been screened. So this is some early analysis and we’re going to continue to review our data of our incidental MGUS cohort and we intend to recruit up to 2,000 patients by the middle of next year so more data to follow.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
